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Studies with animal models are providing new
insights into the pathology of hereditary spastic
paraplegia, particularly how mutations in multiple,
converging pathways can lead to this family of
neuropathies.
Diseases of the nervous system — neuropathies —
are diagnosed on the basis of criteria that include the
affected nerve populations, age of onset and
pathological hallmarks. Hereditary spastic paraplegia
(HSP) is characterized by progressive spasticity and
mild weakness in the lower limbs, in some cases
accompanied by additional neurological symptoms
including mental retardation and optic neuropathy [1].
Typically, the longest nerve fibers — those innervating
the lower extremities — are the earliest to be affected,
and these exhibit a dying back neuropathy in which
damage to terminal and preterminal regions precede
changes in cell bodies. This led to suggestions that
axonal transport might be specifically affected in HSP,
an idea that was reinforced by the discovery that a
kinesin heavy chain mutation is responsible for some
cases of HSP [2]. But the family of HSP diseases may
be caused by defects in any one of over 20 genes,
some of which are expressed in neurons whereas
others are only in myelinating glial cells [1,3]. In recent
months, three papers [4–6] have reported the use of
animal models of HSP to provide new evidence
suggesting that many of the various mutations in
axonal and glial cell proteins may lead to HSP through
convergent pathways. 
Two of these papers [4,5] looked at axonal and
synaptic changes in response to the expression of
mutant proteins by myelinating glia. Yin et al. [4] report
the changes in synaptic terminal structure and
function that result when axons are myelinated by glia
overexpressing protein 0 (P0), the dominant protein of
peripheral nerve myelin. P0 overexpression prevents
proper targeting of other myelin-related proteins,
resulting in an overabundance of Schwann cells and a
failure to generate myelinated internodes. Although
this Schwann cell abnormality does not appear to
affect axon maturation in terms of axon caliber and
initial muscular innervation, it causes problems in the
ability of neurons to maintain their terminal connec-
tions with muscle. Yin et al. [4] stress the importance
of synaptic degeneration preceding axonal degenera-
tion — ‘dying back’ neuropathy — but they fail to
explain why the terminals, which appear to form nor-
mally, are not maintained. They do, however, suggest
that some, as yet unidentified, molecules that are
needed to maintain the terminals are not transported
efficiently with this form of dysmyelination.
Edgar et al. [5] examined an animal model of HSP
with a defect in another myelin protein, PLP.
Mutations of PLP can cause HSP in humans [3] and in
animal models [7]. What they observed was the accu-
mulation of retrogradely transported organelles,
mainly in distal portions of axoplasm underlying nodes
of Ranvier adjacent to abnormal myelin sheaths. The
accumulations occurred in nerves from PLP null mice,
in which all myelin lacks PLP; they were also observed
in the limited number of myelin segments formed
when glia from PLP null mice were transplanted into
the spinal cords of shiverer mutant mice, which
normally lack myelin basic protein and myelin sheaths.
The transplanted mutant glia form patches of myelin
that lacks PLP and vesicle accumulations were seen
only in axon segments surrounded by mutant myelin.
These results suggested a specific local effect of
the myelin sheath on retrograde axonal transport.
Consistent with this, Edgar et al. [5] found that the
accumulation of a tracer, fluorescent cholera toxin, in
retinal ganglion cell bodies after injection into the
superior colliculus was diminished in PLP null mice. A
defect in retrograde signaling had previously been
suggested to underlie some forms of HSP, given
indications that abnormal endosome function is
associated with this neuropathy [8–11]. The mecha-
nism by which changes in a myelin sheath could affect
retrograde axonal transport remains to be determined,
but previous studies [12,13] had demonstrated that
changes in axonal signaling are associated with myeli-
nation. Myelin sheaths were found to have both local
effects on axonal kinases and phosphatases, as well
as altering retrograde signaling [12] and neuronal gene
expression [13]. 
In the third paper, published recently in Current
Biology, Trotta et al. [6] examined the effect of
changing expression levels of D-spastin — the human
homolog of which is linked to 40% of HSP cases — on
synaptic terminal stability and function in Drosophila.
Using genetics and RNA interference (RNAi) methods,
the authors either overexpressed or underexpressed
D-spastin — 60% similar in sequence to mammalian
spastin — selectively in the Drosophila nervous
system and muscle. Presumably through interactions
with microtubules, D-spastin influences synaptic
properties at the Drosophila neuromuscular junction.
Overexpression of neuronal D-spastin caused under-
growth of synaptic terminals and diminished activity;
in contrast, reduction of D-spastin by RNAi increased
synaptic activity. 
Spastin is known to affect microtubule dynamics in
mammals [14], so Trotta et al. [6] examined how
varying the D-spastin level affects microtubule
dynamics in Drosophila neurons by measuring
changes in tubulin acetylation, a common marker for
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microtubule dynamics. As predicted, overexpression
of D-spastin decreased tubulin acetylation levels, and
downregulation of D-spastin had the opposite effect.
Complementary effects on Drosophila synaptic func-
tion were seen with agents that either stabilize (taxol)
or destabilize (nocodazole) microtubules. Remarkably,
changes in myelination of mammalian nerves can also
alter microtubule dynamics [15,16]. Again the specific
pathways that connect changing microtubule dynam-
ics and synaptic function is unclear, though agents
that affect microtubule dynamics have long been
known to affect fast axonal transport and spastin may
influence the delivery and/or removal of synaptic pro-
teins via an effect on transport. 
Changes in the anterograde or retrograde transport
of vesicles continue to be implicated in the pathogen-
esis of dying back neuropathies. Consistent with such
a mechanism are reports that mutations in kinesin
heavy chain isoforms are responsible for some forms
of both HSP [2] and Charcot-Marie-Tooth type 2a [17].
Similarly, dynein heavy chain mutations can produce
spinal muscular atrophy [18]. The challenge has been
to understand how 20 genes implicated in HSP could
produce a similar spectrum of pathological changes.
This was particularly challenging for genes expressed
only in myelin. The latest findings [4–6] indicate there
are connections between myelinating glia and vesicle
transport in axons. Once axons begin to interact with
myelinating glial cells, glia begin influencing both
vesicle transport in the axon and retrograde signaling
in the neuron. Changes in vesicle transport, and con-
sequent changes in retrograde signaling, in turn affect
the ability of a neuron to maintain functional connec-
tions with its targets. Alterations in these pathways,
whether due to changes in motors, the cytoskeleton
or the pathways regulating them, can produce synap-
tic degeneration and the dying back neuropathy char-
acteristic of HSP.
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